Recent Company News

• 02:42 AM ET Sep 14, 2026
  

  SanBio reports H1 net income attributable (¥1.79B) vs guidance (¥2.91B)

• 02:01 PM ET Jul 27, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 20-Jul

• 07:08 AM ET Jul 22, 2026
  

  Royalty Pharma acquires royalty interest in AstraZeneca's (AZN.LN) cliramitug for up to $425M from Neurimmune ($58.42, 0.00)

• 05:35 PM ET Jul 15, 2026
  

  SanBio upgraded to buy from neutral at Citi (¥1050.0000, 0)

• 07:30 AM ET Jun 15, 2026
  

  SanBio upgraded to hold at Jefferies (¥1210.0000, 0)

• 02:38 AM ET Jun 15, 2026
  

  SanBio reports Q1 net income attributable (¥836M) vs FactSet (¥821.7M) [2 est, (¥1.20)-(443.5M)] (¥1210.0000, 0)

• 02:38 AM ET May 21, 2026
  

  SanBio launches sales of AKUUGO intracerebral transplant injection for treatment for traumatic brain injury today (¥1518.0000, 0)

• 02:54 AM ET May 20, 2026
  

  Japan Central Social Insurance Medical Council confirms price for SanBio's AKUUGO injection at ¥72.7M (¥1429.0000, 0)

• 11:12 PM ET May 12, 2026
  

  SanBio raises FY guidance following approval of proposed drug price for AKUUGO (¥2530.0000, +293)

• 02:57 AM ET Apr 23, 2026
  

  SanBio expects to begin in Japan sales of Akuugo in H1, first dose of Akuugo in H2 this year (¥2123.0000, 0)